Atlas Trials

Primary Immunodeficiency Diseases (PID)

25 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Primary Immunodeficiency Diseases (PID)

RecordFirmDate
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) (NCT05150340)Takeda2022-01-24
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) (NCT04346108)Baxalta now part of Shire2020-08-11
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN) (NCT03716700)Baxalta now part of Shire2018-09-24
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects (NCT03277313)Baxalta now part of Shire2017-09-25
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) (NCT02593188)Baxalta now part of Shire2015-11-12
Phase 2/3 Study of IGSC, 20% in PIDD (NCT01218438)Baxalta now part of Shire2013-01-28
Immune Globulin Subcutaenous (Human), 20% (NCT01412385)Baxalta now part of Shire2011-06-20
Gammagard Liquid and rHuPH20 in PID (NCT00814320)Baxalta now part of Shire2008-12-18
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects (NCT00546871)Baxalta now part of Shire2007-10-03
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously (NCT00782106)Baxalta now part of Shire2006-12-04
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders (NCT00157079)Baxalta now part of Shire2002-06-25
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) (NCT00161993)Baxalta now part of Shire2002-06-13

Track Primary Immunodeficiency Diseases (PID) automatically

Every clearance here is in the API, with alerts when new ones post.